Pediatric Obesity and GLP-1 Agonists: Are We Ready for Pharmacologic Therapy in Children?

Introduction

Pediatric obesity has emerged as one of the most significant public health challenges of the twenty-first century, affecting millions of children and adolescents worldwide. Contemporary evidence clearly demonstrates that pediatric obesity is not simply the result of poor dietary choices, inadequate physical activity, lack of motivation, or insufficient counseling. Rather, it is a complex, chronic, and multifactorial disease that arises from the interaction of genetic susceptibility, biological regulation of energy balance, environmental influences, behavioral factors, psychosocial stressors, socioeconomic conditions, and family dynamics. These interconnected factors create a physiological and social environment that promotes excessive weight gain and makes long term weight management particularly challenging.

The pathogenesis of pediatric obesity involves sophisticated neuroendocrine pathways that regulate hunger, satiety, energy expenditure, and fat storage. Genetic factors influence an individual’s predisposition to weight gain, while hormonal systems involving leptin, ghrelin, insulin, and other appetite-regulating mediators affect energy balance throughout childhood and adolescence. Environmental influences, including the widespread availability of calorie-dense foods, reduced opportunities for physical activity, increased screen time, disrupted sleep patterns, and chronic psychosocial stress, further contribute to obesity risk. In addition, certain medications, endocrine disorders, and adverse social determinants of health such as food insecurity, limited access to healthcare, and neighborhood characteristics can significantly influence weight trajectories during childhood.

Importantly, the health consequences of pediatric obesity often begin long before adulthood. Excess adiposity during childhood and adolescence is associated with a broad spectrum of metabolic, cardiovascular, respiratory, reproductive, musculoskeletal, and psychological complications. Many adolescents with obesity already exhibit insulin resistance, impaired glucose metabolism, and type 2 diabetes mellitus, conditions that were once considered largely confined to adult populations. Elevated blood pressure, dyslipidemia, and early vascular dysfunction contribute to increased long term cardiovascular risk. Hepatic complications, particularly metabolic dysfunction associated steatotic liver disease, have become increasingly prevalent among youth with obesity and may progress to fibrosis and advanced liver disease if left untreated.

The reproductive consequences are also substantial. Adolescent females may develop polycystic ovary syndrome, characterized by menstrual irregularities, hyperandrogenism, and metabolic dysfunction. Respiratory complications such as obstructive sleep apnea can impair sleep quality, cognitive performance, and daytime functioning. Orthopedic problems, including joint pain, musculoskeletal strain, and mobility limitations, may further reduce physical activity and worsen weight gain. Equally important are the psychosocial effects of obesity. Many children and adolescents experience depression, anxiety, social isolation, low self-esteem, bullying, weight-based discrimination, and reduced quality of life. The cumulative impact of these physical and psychological complications reinforces the need to view pediatric obesity as a serious chronic disease rather than a cosmetic or lifestyle concern.

Lifestyle and behavioral interventions remain the foundation of pediatric obesity treatment. Evidence consistently supports comprehensive approaches that incorporate nutritional counseling, increased physical activity, behavioral modification techniques, sleep optimization, and family engagement. Family-based interventions are particularly important because caregivers play a central role in shaping dietary habits, activity patterns, and home environments. However, despite their effectiveness, intensive behavioral programs are often difficult to access. Many families face barriers related to cost, transportation, time commitments, healthcare availability, and socioeconomic constraints. As a result, many patients receive less intensive counseling that may produce only modest or unsustained weight reduction.

These limitations have contributed to a paradigm shift in pediatric obesity management toward a comprehensive chronic disease model. Similar to the management of asthma, diabetes, or hypertension, obesity is increasingly recognized as a condition that may require long term, multimodal treatment strategies. This approach combines lifestyle modification with pharmacotherapy, metabolic and bariatric surgery for selected patients, and ongoing clinical follow up to address disease progression and associated comorbidities. The goal is not simply weight reduction but also improvement in metabolic health, physical functioning, psychological well-being, and long term health outcomes.

Among recent therapeutic advances, glucagon-like peptide-1 receptor agonists have generated considerable interest due to their ability to produce clinically meaningful weight reduction in adolescents with obesity. These medications act through multiple mechanisms, including appetite suppression, delayed gastric emptying, and enhanced satiety signaling, leading to reductions in caloric intake and body weight. Clinical trials have demonstrated significant improvements in body mass index and several obesity-related comorbidities, suggesting that these agents may represent an important addition to the pediatric obesity treatment armamentarium.

Despite their promise, enthusiasm for GLP-1 receptor agonists must be balanced with careful consideration of their limitations and long term implications. Children and adolescents are in critical stages of physical growth, neurocognitive development, emotional maturation, and identity formation. The long term effects of extended pharmacologic treatment during these developmental periods remain incompletely understood. Questions persist regarding optimal treatment duration, long term safety, maintenance of weight loss after discontinuation, and potential effects on growth and developmental outcomes.

Practical considerations also influence the role of GLP-1 receptor agonists in clinical practice. Sustained adherence may be challenging, particularly among adolescents navigating increasing independence and complex psychosocial environments. Medication costs can be substantial, creating barriers to access and raising concerns about healthcare equity. Furthermore, ongoing monitoring is essential to evaluate treatment efficacy, manage adverse effects, assess nutritional status, and support adherence. Clinicians must engage patients and families in shared decision-making processes that carefully weigh potential benefits against risks, burdens, and individual circumstances.

As the understanding of pediatric obesity continues to evolve, treatment strategies are increasingly moving toward personalized, multidisciplinary models of care. Effective management requires collaboration among pediatricians, endocrinologists, dietitians, psychologists, exercise specialists, social workers, and families. Future advances will likely depend on integrating biological insights with behavioral, social, and environmental interventions that address the full complexity of the disease.

Ultimately, pediatric obesity should be recognized as a chronic, relapsing, and multifaceted medical condition that demands comprehensive and compassionate care. While lifestyle modification remains essential, the emergence of pharmacologic therapies such as GLP-1 receptor agonists reflects a broader shift toward evidence-based, individualized treatment approaches. The challenge for clinicians is to balance innovation with caution, ensuring that therapeutic advances improve health outcomes while supporting the long term physical, emotional, and developmental needs of children and adolescents living with obesity.

Mechanism of Action

The management of pediatric and adolescent obesity has undergone a significant transformation with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications represent a major advancement in obesity treatment because they target underlying physiological mechanisms involved in appetite regulation, energy intake, and metabolic control rather than relying solely on behavioral interventions. As obesity rates continue to rise among children and adolescents worldwide, understanding the pharmacology, clinical applications, and safety considerations of GLP-1 receptor agonists has become increasingly important for pediatricians, endocrinologists, obesity medicine specialists, and primary care providers.

GLP-1 receptor agonists are synthetic analogs of glucagon-like peptide-1, a naturally occurring incretin hormone secreted primarily by enteroendocrine L cells in the distal small intestine and colon in response to nutrient ingestion. Under normal physiological conditions, GLP-1 plays a critical role in maintaining glucose homeostasis and regulating energy balance through multiple interconnected pathways.

These agents exert their effects by binding to and activating GLP-1 receptors located throughout the body, including the pancreas, gastrointestinal tract, cardiovascular system, and central nervous system. Activation of pancreatic GLP-1 receptors enhances glucose-dependent insulin secretion from beta cells while simultaneously suppressing inappropriate glucagon secretion from alpha cells. Because insulin release is dependent on circulating glucose concentrations, the risk of hypoglycemia is substantially lower than with many traditional antidiabetic medications when GLP-1 receptor agonists are used as monotherapy.

Beyond their effects on glycemic regulation, GLP-1 receptor agonists influence appetite and feeding behavior through direct actions on the central nervous system. Receptors located within the hypothalamus and other appetite-regulating brain regions respond to GLP-1 signaling by reducing hunger sensations and enhancing satiety. As a result, patients typically experience decreased food cravings, reduced meal size, and lower overall caloric intake.

Current evidence indicates that the weight reduction associated with GLP-1 receptor agonists is driven predominantly by decreased energy consumption rather than a substantial increase in energy expenditure. This distinction is important because it highlights the role of these therapies in modifying eating behavior and physiological hunger signals rather than directly increasing metabolic rate.

Another important mechanism involves delayed gastric emptying. By slowing the movement of food from the stomach into the small intestine, GLP-1 receptor agonists prolong feelings of fullness after meals and contribute to reduced caloric intake. While this effect enhances weight loss efficacy, it also contributes to many of the gastrointestinal adverse effects associated with treatment, including nausea, vomiting, abdominal discomfort, bloating, and early satiety.

The impact on gastric motility has become increasingly relevant in clinical practice, particularly in perioperative and procedural settings. Delayed gastric emptying may increase concerns regarding aspiration risk during anesthesia, procedural sedation, and surgical interventions. Consequently, clinicians should carefully evaluate medication timing and fasting requirements before planned procedures in patients receiving GLP-1 receptor agonist therapy.

Importantly, GLP-1 receptor agonists should not be characterized simply as appetite suppressants. Such terminology fails to capture the broad physiological effects of these medications. They are more accurately described as incretin-based metabolic therapies that influence multiple biological pathways, including appetite regulation, satiety signaling, glucose metabolism, gastric motility, insulin secretion, glucagon suppression, and cardiometabolic risk factors. Emerging evidence also suggests beneficial effects on cardiovascular outcomes, insulin resistance, and markers of systemic inflammation.

Current FDA-Approved GLP-1 Options for Adolescent Obesity

Currently, two GLP-1 receptor agonists play a central role in the pharmacologic management of obesity among adolescents in the United States: liraglutide and semaglutide. Both medications are approved as adjuncts to comprehensive lifestyle interventions that include nutritional counseling, increased physical activity, and behavioral modification strategies.

Liraglutide

Liraglutide is a long-acting GLP-1 receptor agonist approved for chronic weight management in pediatric patients aged 12 years and older who have obesity and a body weight exceeding 60 kilograms. The medication is administered as a once-daily subcutaneous injection and requires gradual dose escalation to improve gastrointestinal tolerability.

Treatment is typically initiated at a low dose and increased incrementally over several weeks until the recommended maintenance dose of 3 mg daily is reached. In situations where patients are unable to tolerate the full maintenance dose because of adverse gastrointestinal effects, a maintenance dose of 2.4 mg daily may be considered. However, if a patient cannot tolerate 2.4 mg daily, discontinuation of therapy is recommended because lower doses are unlikely to provide clinically meaningful weight management benefits.

Response assessment is an important component of treatment monitoring. Clinical guidelines recommend evaluating treatment effectiveness after 12 weeks on the maintenance dose. If body mass index has not decreased by at least 1 percent during this period, continued therapy is generally considered unlikely to produce remarkable long-term benefit, and alternative management strategies should be considered.

Semaglutide

Semaglutide represents a newer generation GLP-1 receptor agonist with an extended duration of action that allows for once-weekly administration. It is approved for chronic weight management in pediatric patients aged 12 years and older with obesity and has demonstrated substantial efficacy in reducing body weight in clinical trials.

The approved obesity treatment regimen involves gradual dose escalation over several months until the target maintenance dose of 2.4 mg administered subcutaneously once weekly is achieved. The slower titration schedule helps minimize gastrointestinal adverse effects and improves treatment adherence.

For adolescent obesity management, the injectable formulation is the relevant FDA-approved product. Clinicians should exercise caution when discussing alternative formulations, as approval status, safety profiles, and efficacy data may differ between products. The availability of oral semaglutide formulations for other indications should not be interpreted as evidence of safety or effectiveness for pediatric obesity unless supported by specific regulatory approval and pediatric clinical trial data.

Safety and Medication Reconciliation Considerations

A critical aspect of GLP-1 receptor agonist prescribing involves careful medication reconciliation and avoidance of therapeutic duplication. Neither liraglutide nor semaglutide should be used concurrently with another GLP-1 receptor agonist or with another product containing the same active ingredient.

This consideration is particularly important in adolescent populations, where patients may receive care from multiple healthcare providers, including pediatricians, endocrinologists, obesity medicine specialists, and telehealth services. Medication histories may include prescriptions intended for diabetes management, obesity treatment, compounded formulations, or medications obtained through online prescribing platforms. Failure to identify overlapping therapies may increase the risk of adverse effects without providing additional clinical benefit.

Comprehensive medication reviews should therefore be conducted before initiating treatment and repeated regularly throughout therapy. Providers should verify all prescription medications, over-the-counter products, supplements, and compounded formulations to ensure safe and coordinated care.

Clinical Role in Adolescent Obesity Management

The introduction of GLP-1 receptor agonists has expanded treatment options for adolescents with obesity, particularly those who have not achieved adequate weight reduction through lifestyle interventions alone. These medications address key biological drivers of obesity by modifying appetite regulation, satiety signaling, and metabolic function. However, they should be viewed as components of a comprehensive obesity management strategy rather than stand-alone solutions.

Successful long-term treatment requires integration with nutritional counseling, physical activity promotion, behavioral support, family engagement, and ongoing clinical monitoring. As evidence continues to evolve, GLP-1 receptor agonists are increasingly recognized as important tools in the management of pediatric obesity, offering the potential to improve weight outcomes, metabolic health, and long-term cardiometabolic risk in appropriately selected patients.

Evidence for Liraglutide

The pivotal liraglutide trial enrolled adolescents aged 12 to 17 years with obesity and evaluated liraglutide 3 mg daily as an adjunct to lifestyle therapy. Liraglutide produced a greater reduction in BMI than placebo over 56 weeks. More adolescents receiving liraglutide achieved at least 5% and at least 10% BMI reduction compared with placebo.

The effect was clinically meaningful but not dramatic compared with later semaglutide data. Gastrointestinal adverse effects were common, and weight regain occurred after discontinuation. This pattern reinforces that obesity pharmacotherapy should be approached as chronic treatment, not as a short course that permanently resets weight biology.

Liraglutide may remain useful when weekly semaglutide is unavailable, not covered, not tolerated, or not preferred. Its daily dosing can be a barrier for adolescents, but it also allows faster discontinuation if adverse effects occur.

Evidence for Semaglutide

The STEP TEENS trial evaluated semaglutide 2.4 mg weekly in adolescents with obesity, or overweight with at least one weight-related comorbidity, as an adjunct to lifestyle intervention. Semaglutide produced substantially greater BMI reduction than placebo at 68 weeks and improved several cardiometabolic markers.

Semaglutide is the most effective FDA-approved GLP-1 receptor agonist for adolescent obesity based on currently available trial data. However, the trial duration remains short relative to the possible duration of real-world therapy. The evidence supports use in selected adolescents, but it does not answer all questions about years of exposure, discontinuation strategies, effects on body composition, long-term bone health, reproductive health, eating-disorder risk, or lifelong cardiometabolic outcomes.

Tirzepatide and Other Emerging Incretin Therapies

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is relevant in pediatrics for type 2 diabetes in patients aged 10 years and older under the diabetes indication. It should not be described as an FDA-approved pediatric obesity medication unless that specific indication is confirmed in current labeling.

Adolescent obesity trials of tirzepatide are important, but until pediatric obesity data and labeling are available, tirzepatide should be discussed as an emerging therapy rather than a standard pediatric obesity option.

Other incretin-based and appetite-pathway therapies are in development. These may eventually broaden treatment options, but articles for clinicians should distinguish approved pediatric indications from adult data, off-label use, and investigational therapy.

Table 1. Pediatric and Adolescent Anti-Obesity Medication Context

Medication	Pediatric obesity role	Key clinical caveat
Liraglutide 3 mg daily	FDA-approved for adolescents aged 12 years and older with obesity and body weight greater than 60 kg	Daily injection; GI effects; discontinue if inadequate BMI response after maintenance dosing
Semaglutide 2.4 mg weekly injection	FDA-approved for adolescents aged 12 years and older with obesity	Highest average BMI reduction among approved GLP-1 options; weekly injection; long-term data limited
Phentermine/topiramate ER	FDA-approved for chronic weight management in adolescents aged 12 years and older with obesity	Teratogenic risk from topiramate; mood, cognitive, heart-rate, and sympathomimetic concerns; tapering required at high dose
Orlistat	FDA-approved in adolescents aged 12 years and older	Modest efficacy; GI adverse effects; fat-soluble vitamin supplementation considerations
Setmelanotide	FDA-approved for selected rare genetic or hypothalamic obesity indications in younger pediatric age groups	Not for common polygenic obesity; requires appropriate diagnostic confirmation
Tirzepatide	Pediatric relevance for type 2 diabetes in patients aged 10 years and older; pediatric obesity role remains emerging	Do not present as pediatric obesity-labeled unless current labeling confirms that indication
Metformin	Not FDA-approved for obesity treatment	May be useful for type 2 diabetes, prediabetes, insulin resistance, or PCOS context, but weight effect is modest

Patient Selection

The best candidates are adolescents aged 12 years and older with obesity who have received or are receiving structured lifestyle and behavioral treatment, who have persistent obesity or obesity-related comorbidities, and who can participate in long-term follow-up. Treatment should be family-centered, non-stigmatizing, and developmentally appropriate.

A practical pretreatment assessment should include obesity severity, growth pattern, pubertal status, blood pressure, glycemic status, lipids, liver enzymes when indicated, sleep apnea risk, menstrual history when relevant, medication contributors to weight gain, mental health history, eating-disorder screening, pregnancy potential, family history of medullary thyroid carcinoma or MEN2, pancreatitis history, gallbladder disease, renal risk, gastrointestinal disease, and insurance or access barriers.

Clinicians should avoid presenting GLP-1 therapy as a reward, punishment, or cosmetic intervention. It is medical therapy for a chronic disease and should be discussed in the same evidence-based, nonjudgmental way as treatment for hypertension, diabetes, or asthma.

Safety, Contraindications, and Monitoring

Liraglutide and semaglutide carry boxed warnings about thyroid C-cell tumors observed in rodents. Human relevance remains uncertain, but these medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2. Routine calcitonin or thyroid ultrasound screening has uncertain value unless clinically indicated.

Gastrointestinal adverse effects are the most common reason for intolerance. Nausea, vomiting, diarrhea, constipation, reflux symptoms, and abdominal pain are dose-related and often occur during escalation. Slower titration, hydration counseling, smaller meals, reduced high-fat intake, and temporary dose-holding can improve tolerability.

Pancreatitis is uncommon but clinically important. Families should be instructed to stop the medication and seek care for persistent severe abdominal pain, especially if radiating to the back or associated with vomiting. Gallbladder disease should be considered when abdominal pain, fever, jaundice, or right upper quadrant symptoms occur, especially during rapid weight loss.

Volume depletion can occur when vomiting or diarrhea leads to dehydration. Clinicians should monitor for dizziness, orthostasis, reduced oral intake, acute kidney injury risk, and the need to hold or slow escalation during intercurrent illness. This is particularly important for adolescents with diabetes, renal disease, eating disorders, intense athletic participation, or limited access to hydration.

Hypoglycemia is uncommon in adolescents without diabetes but becomes important when GLP-1-based therapy is used with insulin or insulin secretagogues. Adolescents with type 2 diabetes may need glucose monitoring and adjustment of insulin or sulfonylurea therapy.

Heart rate may increase with GLP-1 therapy. Baseline and follow-up pulse and blood pressure should be documented, particularly in patients with palpitations, dysautonomia, stimulant use, anxiety, or other cardiovascular concerns.

Pregnancy should be addressed before and during therapy in patients with pregnancy potential. Weight-management medications are not appropriate during pregnancy. Semaglutide should be discontinued at least 2 months before planned pregnancy because of its long half-life. Contraception counseling should be handled confidentially and developmentally appropriately.

Table 2. GLP-1 Safety Monitoring for Adolescents

Safety issue	What to assess	Practical response
MTC or MEN2 risk	Personal or family history of medullary thyroid carcinoma or MEN2	Contraindication
GI intolerance	Nausea, vomiting, diarrhea, constipation, abdominal pain, reduced intake	Slow escalation, hold dose, reduce dose, assess hydration
Pancreatitis symptoms	Persistent severe abdominal pain, vomiting, pain radiating to back	Stop medication and evaluate urgently
Gallbladder disease	Right upper quadrant pain, fever, jaundice, postprandial pain	Evaluate with labs and imaging when clinically indicated
Dehydration or AKI risk	Vomiting, diarrhea, poor intake, orthostasis, renal disease	Hydration plan, consider holding medication during illness
Hypoglycemia	Diabetes, insulin, sulfonylurea use	Monitor glucose and adjust glucose-lowering therapy
Heart-rate increase	Baseline and follow-up pulse, palpitations	Monitor and reassess risk-benefit if persistent
Pregnancy potential	Menstrual history, pregnancy testing when appropriate, contraception needs	Avoid in pregnancy; stop semaglutide at least 2 months before planned pregnancy
Eating-disorder risk	Restriction, purging, binge eating, body-image distress	Screen before and during therapy; involve behavioral health
Perioperative aspiration risk	Upcoming anesthesia or deep sedation, GI symptoms, GLP-1 timing	Coordinate with anesthesia and local perioperative guidance

Compounded and Counterfeit Products

Clinicians should be explicit that FDA-approved products are not interchangeable with compounded, counterfeit, or research-use products. Compounded semaglutide and tirzepatide products may vary in concentration, formulation, instructions, and quality oversight. Dosing errors can occur when patients or clinicians convert milligrams to milliliters or “units,” particularly with multi-dose vials and syringes.

Adolescents should not receive compounded GLP-1 products from unverified online sources, spas, or nonmedical weight-loss programs. If a compounded product is considered because of a legitimate clinical need, clinicians should document the rationale, verify the pharmacy, provide precise dosing education, and discuss the lack of FDA premarket review for safety, effectiveness, and quality.

Duration of Therapy and Discontinuation

Obesity is chronic, and weight regain after stopping GLP-1 therapy is expected in many patients. This should be discussed before treatment starts. Families often ask whether the medication is temporary. A more honest answer is that the treatment plan should be reassessed over time, but long-term therapy may be needed to maintain benefit.

Discontinuation may be appropriate for intolerable adverse effects, inadequate response after an adequate trial at the maintenance dose, pregnancy, pancreatitis, serious hypersensitivity, patient preference, cost barriers, or a shift to another treatment strategy. When stopping therapy, clinicians should plan follow-up rather than allowing silent loss to care.

Equity and Access

Access is one of the major determinants of real-world benefit. GLP-1 medications are expensive, coverage is inconsistent, and prior authorization processes can be burdensome. Families with fewer resources may face the highest obesity-related risk and the greatest difficulty obtaining therapy.

A responsible article should not describe these medications as a simple solution if the system cannot deliver equitable access, monitoring, nutrition support, behavioral care, and longitudinal follow-up. Without attention to access, pharmacotherapy may widen disparities rather than reduce them.

Comparison With Surgery

Metabolic and bariatric surgery remains the most effective treatment for many adolescents with severe obesity, especially when substantial comorbidity is present. GLP-1 therapy may delay, complement, or serve as an alternative to surgery for some patients, but it should not be presented as equivalent to surgery based on short-term BMI reduction alone.

Surgery has different risks, benefits, durability data, nutritional consequences, and follow-up requirements. The decision between medication, surgery, or combined approaches should occur in a multidisciplinary setting with careful attention to patient preference, comorbidity severity, psychosocial readiness, and access.

Practical Implementation

A pediatric GLP-1 program should include defined eligibility criteria, standardized pretreatment screening, consent and assent discussions, medication education, injection training, dose-escalation protocols, adverse-effect management, reproductive counseling when relevant, behavioral-health screening, nutrition support, physical activity counseling, and a clear monitoring schedule.

Follow-up should be frequent during dose escalation and at least every 1 to 3 months during early maintenance. Visits should assess BMI trajectory, adverse effects, adherence, injection technique, dietary intake, hydration, blood pressure, pulse, comorbidities, mental health, and medication access.

The goal is not only BMI reduction. Treatment should aim to improve health, function, comorbidity burden, quality of life, and long-term risk while reducing stigma and preserving normal growth and development.

Table 3. Suggested Pretreatment and Follow-up Framework

Stage	Assessment	Key purpose
Baseline	BMI class, growth chart, pubertal status, BP, pulse, comorbidities	Confirm indication and risk profile
Baseline labs	HbA1c or fasting glucose, lipids, liver enzymes when indicated	Identify comorbidities and treatment targets
Safety screen	MTC/MEN2 history, pancreatitis, gallbladder disease, renal risk, GI disease	Avoid contraindicated or high-risk use
Behavioral health	Depression, anxiety, eating disorder, bullying, weight stigma	Prevent harm and align support
Reproductive health	Pregnancy potential, contraception counseling, pregnancy testing when appropriate	Avoid fetal exposure
Dose escalation	GI symptoms, hydration, adherence, injection technique	Improve tolerability and safety
Maintenance	BMI trajectory, BP, pulse, comorbidities, side effects, access	Assess benefit, continuation, or discontinuation
Transition planning	Adult-care handoff, insurance continuity, self-management	Prevent treatment interruption

Table 4. Final “Ready or Not” Clinical Position

Question	Practical answer
Are GLP-1 agents appropriate for all children with high BMI?	No. Current obesity use is primarily for selected adolescents aged 12 years and older who meet criteria.
Should lifestyle therapy be stopped once medication begins?	No. Pharmacotherapy is an adjunct to nutrition, activity, behavioral, sleep, and family-based care.
Is semaglutide more effective than liraglutide?	Trial data show larger average BMI reduction with semaglutide, but tolerability, access, dosing preference, and label criteria matter.
Is tirzepatide a pediatric obesity medication?	Not unless current product labeling confirms a pediatric obesity indication. Pediatric relevance currently centers on type 2 diabetes.
Are compounded GLP-1 products acceptable substitutes?	They should not be treated as equivalent to FDA-approved products and require strong caution because of dosing and quality concerns.
Is lifelong therapy required?	Not always, but long-term treatment may be needed to maintain benefit. Discontinuation should be planned and monitored.

Are We Ready?

The medical community is ready for pharmacologic treatment of adolescent obesity when treatment is evidence-based, label-concordant, family-centered, and embedded in comprehensive care. The field is not ready if GLP-1 therapy is prescribed without screening, follow-up, nutrition and behavioral support, contraindication review, or a plan for long-term management.

For selected adolescents, GLP-1 receptor agonists represent a meaningful advance. For younger children with common obesity, current GLP-1 obesity evidence is insufficient. For adolescents with obesity and serious comorbidities, delaying effective therapy solely because lifestyle-only care has failed repeatedly may also be harmful.

The best position is neither enthusiasm without safeguards nor therapeutic nihilism. GLP-1 therapy should be used thoughtfully, monitored carefully, and paired with the broader treatment infrastructure that pediatric obesity requires.

References

American Academy of Pediatrics. (2023). Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 151(2), e2022060640.

Centers for Disease Control and Prevention. (2025). Prescriptions for obesity medications among adolescents aged 12 to 17 years with obesity, United States, 2018 to 2023. Morbidity and Mortality Weekly Report.

Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756.

Hannon, T. S., et al. (2025). Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes: SURPASS-PEDS. The Lancet.

Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. New England Journal of Medicine, 382(22), 2117-2128.

Kelly, A. S., Bensignor, M. O., Hsia, D. S., Shoemaker, A. H., Shih, W., Peterson, C., Varghese, S. T., & Arslanian, S. (2022). Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evidence, 1(6).

Mead, E., Brown, T., Rees, K., Azevedo, L. B., Whittaker, V., Jones, D., et al. (2017). Diet, physical activity and behavioural interventions for the treatment of overweight or obesity in children. Cochrane Database of Systematic Reviews.

Pratt, J. S. A., Browne, A., Browne, N. T., Bruzoni, M., Cohen, M., Desai, A., et al. (2018). ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surgery for Obesity and Related Diseases, 14(7), 882-901.

Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017). Pediatric obesity assessment, treatment, and prevention: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 102(3), 709-757.

U.S. Food and Drug Administration. Current prescribing information for Saxenda, Wegovy, Mounjaro, Qsymia, Imcivree, and related anti-obesity medications. Verify current product-specific labeling before publication.

Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022). Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, 387(24), 2245-2257.